Preclinical evidence supporting this approach is robust (Figure 3-A), suggesting that early intervention targeting the CXCL10–CXCR3 axis may effectively mitigate both primary tumor progression and the facilitation of metastatic dissemination [71,118,120,171]. This evidence concerns the gene CXCL10 and neoplasm.